PMI: Q4 & FY22 Results

Share on facebook
Share on twitter
Share on email
Share on whatsapp
Share on linkedin

Bottom-line results & Volume progression1

EPS: up +20.8% to $1.23 in Q4; up +11.9% to $5.34 in FY22

Total volume: +2.6% in Q4; 3.2% in FY22 (HnB volume: +37.5% in Q4; +21.5% in FY22)

Adjusted figures: excluding Russia & Ukraine

Operating Income: margin pressures

FY22: 0.6% decline on an organic basis

– inflationary cost pressures (notably related to leaf, acetate tow and energy prices); transitory cost impact associated with the ILUMA roll-out; costs due to supply chain disruptions related to the war in Ukraine

– partly offset by the favorable product mix, pricing and operating efficiencies

FY23: 0.5%-1.5% decline
– continued inflationary cost pressures and ILUMA roll-out associated transitory costs

– incremental investments to drive future growth: ~$150Mn with a broadly even split between the US and Wellness & Healthcare segments

FY23 Guidance

Russia & Ukraine to be included in 2023 figures (PMI Assets: $2.5Bn in Russia, $0.4Bn in Ukraine)

Revenue growth: +7%-8.5% (organic)

EPS growth: +7%-9% to $6.40-$6.52, despite inflationary pressures and ILUMA deployment expenses (top and bottom-line delivery to be second-half weighted; Q1 EPS: $1.28-1.33)

Total PMI volume: flat to +1%, despite 1-2% industry volume decline (ex-China&US)

HnB shipment volume: 125-130Bn (acceleration in growth vs. 2022); Q1 HnB volume: 26-28Bn

Adj. operating margin: 0.5%-1.5% decline

Wellness & Healthcare revenues of $300Mn with an operating loss of $150Mn

Operating cash flow: $10-11 Bn (no share repurchases due to the Swedish Match acquisition)

Our take-away

Trading at 16.9x adj. EPS and 14.3x adj. EV/EBITDA. Dividend yield: 5% (based on Feb 8, 2023 closing price: $101.3)

Top-class management, execution & results vis-a-vis the industry peers. However, the operating margin and EPS guidance are a touch softer than expected (inflationary pressures, ILUMA expansion expenses and “future growth” investments). 21.5% HnB volume growth (37.5% in Q4) is noteworthy. Zyn & IQOS are the current/future growth engines in the US. We continue to like PM which is on the way to a new all-time high (ATH). The timing of the new ATH could coincide with the IQOS launch in the US. Meanwhile, any pullback is a buying opportunity.

References:

  1. https://philipmorrisinternational.gcs-web.com/static-files/4b77c96b-b87a-4bb2-b568-208a14bdaa4c ↩︎

Call Request:
Reports

We will reach out to you within 24 hours to discuss your request. Please note that we only respond to requests with a valid business e-mail address
Disclaimer: The content in our Market Pulse section is/shall not be construed as investment advice. It is for informative purposes only and does not take into account the individual needs, investment objectives and specific financial circumstances. Any action taken upon the information in our Market Pulse section is strictly at the reader’s own risk. We assume no responsibility or liability for the actions taken. Moreover, we also assume no responsibility or liability for any errors or omissions in our content – which is provided on an “as is” basis with no guarantees of completeness, accuracy, usefulness or timeliness even if we only depend on the infromation sources that are believed to be accurate.

Consultation
Session Request

We will reach out to you within 24 hours to discuss your request. Please note that we only respond to requests with a valid business e-mail address